Clonality Analysis for Multicentric Origin and Intrahepatic Metastasis in Recurrent and Primary Hepatocellular Carcinoma

Overview

Journal J Gastrointest Surg

Specialty Gastroenterology

Date 2008 Jul 17

PMID 18629593

Citations 19

Authors

Qiang Li

Jian Wang

Jonathan T Juzi

Yan Sun

Hong Zheng

Yunlong Cui

Haixin Li

Xishan Hao

Affiliations

Soon will be listed here.

Abstract

Aims: To clarify the incidence of multicentric occurrence (MO) and intrahepatic metastasis (IM) for hepatocellular carcinoma (HCC) related to hepatitis B virus in China and to identify the differences between them.

Methods: Histopathologic and genetic features of primary and recurrent tumors in 160 cases with HCC were analyzed. The two groups, the origin of which was definitely determinable as of multicentric occurrence or as of intrahepatic metastasis, were analyzed for their disease-free survival and clinicopathological differences.

Results: According to histopathological findings, 27.5% and 59.4% patients were considered to be MO and IM, respectively. By comparing the genetic information of loss of heterozygosity and microsatellite instability for 10 different markers between primary and recurrent tumor, 30.0% and 63.8% patients with recurrent HCC were considered to be MO and IM, respectively. In total, 126 cases with unanimous conclusions from the histopathological and genetic method were selected and divided into the MO group (37 cases) and the IM group (89 cases). Analysis of stepwise regression identified that recurrence time, grading, portal vein invasion, tumor number, and Child's stage were the most important discriminating factors between MO and IM (p < 0.05). As for their prognosis, Kaplan-Meier and log rank test showed that the disease-free survival in the MO group was significantly better than in the IM group (p = 0.002).

Conclusions: Combined analysis of histopathological and genetic analysis may reflect more exactly the nature of recurrent HCC. The incidence of MO in China is lower than in other countries--30% compared to up to 50% in Japan [Morimoto et al., Journal of Hepatology 39:215-221, 2003; Yamamoto et al., Hepatology 29;1446-1452, 1999]. Recurrence time, tumor grading, portal vein invasion, tumor number, and Child's stage are the most important discriminating factors between MO and IM. The prognosis (disease-free survival) of patients with MO compared to IM is significantly better.

Citing Articles

Lessons learned from hepatocellular carcinoma may cause a paradigm shift in intraductal papillary mucinous neoplasms: a narrative review and discussion of conceptual similarities in tumor progression and recurrence.

Margonis G, Andreatos N, Wang J, Weiss M, Wolfgang C J Pancreatol. 2024; 5(1):36-40.

PMID: 39640535 PMC: 11619816. DOI: 10.1097/jp9.0000000000000083.

A multicenter propensity score analysis of significance of hepatic resection type for early-stage hepatocellular carcinoma.

Tang S, Zhang K, Lin K, Tang Y, Fu J, Zhou W Hepatol Int. 2023; 18(2):623-635.

PMID: 37880566 DOI: 10.1007/s12072-023-10602-0.

Elevated FAM134B expression induces radiation-sensitive in hepatocellular carcinoma.

Xie B, Xie Y, Fang C, Zhong B, Ye R, Zhang J BMC Cancer. 2023; 23(1):671.

PMID: 37460952 PMC: 10353116. DOI: 10.1186/s12885-023-11030-x.

Transcriptome analysis creates a new era of precision medicine for managing recurrent hepatocellular carcinoma.

Chiang C, Yeh H, Lim S, Lin W World J Gastroenterol. 2023; 29(5):780-799.

PMID: 36816628 PMC: 9932421. DOI: 10.3748/wjg.v29.i5.780.

Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma.

Liang J, Bai Y, Ha F, Luo Y, Deng H, Gao Y World J Gastrointest Oncol. 2023; 15(1):1-18.

PMID: 36684055 PMC: 9850755. DOI: 10.4251/wjgo.v15.i1.1.

References

Arii S, Monden K, Niwano M, Furutani M, Mori A, Mizumoto M . Results of surgical treatment for recurrent hepatocellular carcinoma; comparison of outcome among patients with multicentric carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence. J Hepatobiliary Pancreat Surg. 1998; 5(1):86-92. DOI: 10.1007/pl00009956. View

Kahng Y, Lee Y, Kim B, Park W, Lee J, Kang C . Loss of heterozygosity of chromosome 8p and 11p in the dysplastic nodule and hepatocellular carcinoma. J Gastroenterol Hepatol. 2003; 18(4):430-6. DOI: 10.1046/j.1440-1746.2003.02997.x. View

Koike K, Moriya K, Kimura S . Role of hepatitis C virus in the development of hepatocellular carcinoma: transgenic approach to viral hepatocarcinogenesis. J Gastroenterol Hepatol. 2002; 17(4):394-400. DOI: 10.1046/j.1440-1746.2002.02763.x. View

Ng I, Guan X, Poon R, Fan S, Lee J . Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J Pathol. 2003; 199(3):345-53. DOI: 10.1002/path.1287. View

Maruyama K, Kaminishi M, Hayashi K, Isobe Y, Honda I, Katai H . Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer. 2006; 9(2):51-66. DOI: 10.1007/s10120-006-0370-y. View

Yamamoto T, Kajino K, Kudo M, Sasaki Y, Arakawa Y, Hino O . Determination of the clonal origin of multiple human hepatocellular carcinomas by cloning and polymerase chain reaction of the integrated hepatitis B virus DNA. Hepatology. 1999; 29(5):1446-52. DOI: 10.1002/hep.510290523. View

Shimamatsu K, Kage M, Nakashima O, Kojiro M . Pathomorphological study of HCV antibody-positive liver cirrhosis. J Gastroenterol Hepatol. 1994; 9(6):624-30. DOI: 10.1111/j.1440-1746.1994.tb01572.x. View

Momosaki S, Nakashima Y, Kojiro M, Tabor E . HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma. J Viral Hepat. 2005; 12(3):325-9. DOI: 10.1111/j.1365-2893.2005.00586.x. View

Wong C, Lee J, Lau T, Fan S, Ng I . Clinicopathological significance of loss of heterozygosity on chromosome 13q in hepatocellular carcinoma. Clin Cancer Res. 2002; 8(7):2266-72. View

10.

Tokita H, Fukui H, Tanaka A, Kamitsukasa H, Yagura M, Harada H . Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol. 2005; 20(5):752-8. DOI: 10.1111/j.1440-1746.2005.03800.x. View

11.

Chen Y, Yeh S, Chen J, Wu C, Hsu M, Tsai S . Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology. 2000; 119(2):431-40. DOI: 10.1053/gast.2000.9373. View

12.

Yasui M, Harada A, Nonami T, Takeuchi Y, Taniguchi K, Nakao A . Potentially multicentric hepatocellular carcinoma: clinicopathologic characteristics and postoperative prognosis. World J Surg. 1997; 21(8):860-4; discussion 864-5. DOI: 10.1007/s002689900318. View

13.

Birgisson H, Talback M, Gunnarsson U, Pahlman L, Glimelius B . Improved survival in cancer of the colon and rectum in Sweden. Eur J Surg Oncol. 2005; 31(8):845-53. DOI: 10.1016/j.ejso.2005.05.002. View

14.

Tarao K, Hoshino H, Shimizu A, Ohkawa S, Nakamura Y, Harada M . Role of increased DNA synthesis activity of hepatocytes in multicentric hepatocarcinogenesis in residual liver of hepatectomized cirrhotic patients with hepatocellular carcinoma. Jpn J Cancer Res. 1994; 85(10):1040-4. PMC: 5919356. DOI: 10.1111/j.1349-7006.1994.tb02903.x. View

15.

Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S . Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology. 1997; 25(1):87-92. DOI: 10.1053/jhep.1997.v25.pm0008985270. View

16.

Manno M, Camma C, Schepis F, Bassi F, Gelmini R, Giannini F . Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology. 2004; 127(3):756-63. DOI: 10.1053/j.gastro.2004.06.021. View

17.

McCormack L, Petrowsky H, Clavien P . Surgical therapy of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2005; 17(5):497-503. DOI: 10.1097/00042737-200505000-00005. View

18.

Qiang L, Huikai L, Butt K, Wang P, Hao X . Factors associated with disease survival after surgical resection in Chinese patients with hepatocellular carcinoma. World J Surg. 2006; 30(3):439-45. DOI: 10.1007/s00268-005-0608-6. View

19.

Hao X, Wang P, Chen K, Li Q, He M, Yu S . Twenty-year trends of primary liver cancer incidence rates in an urban Chinese population. Eur J Cancer Prev. 2003; 12(4):273-9. DOI: 10.1097/00008469-200308000-00006. View

20.

Takenaka K, Adachi E, Nishizaki T, Hiroshige K, Ikeda T, Tsuneyoshi M . Possible multicentric occurrence of hepatocellular carcinoma: a clinicopathological study. Hepatology. 1994; 19(4):889-94. View